Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hyloris Lays Out Ambitious Plans For US

Value Added Medicines Specialist Reveals How It Will Use IPO Proceeds

Executive Summary

Fresh from a successful IPO, Belgian value-added medicines specialist Hyloris Pharmaceuticals has the financial firepower it needs to pursue ambitious expansion plans that include building out a US commercial infrastructure, CEO Stijn Van Rompay tells Generics Bulletin in an exclusive interview.

You may also be interested in...



Value-Added Specialist Hyloris Launches IPO

Value-added medicines specialist Hyloris Pharmaceuticals is launching an IPO to provide the funds it needs to focus on opportunities through the US 505(b)(2) pathway.

Hyloris Funding Round Raises €15m

Belgian value-added medicines specialist Hyloris Pharmaceuticals says it has raised €15m through a funding round that will give it the firepower to pursue 505(b)(2) applications in the US.

Teva Sees COVID Sales Correction

In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.

Topics

UsernamePublicRestriction

Register

LL1133377

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel